6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
11 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.
November 2023 in “Pakistan Journal of Health Sciences” Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
May 2015 in “HAL (Le Centre pour la Communication Scientifique Directe)” APIs' stability is influenced by crystalline forms, pressure, and water.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
26 citations
,
July 2007 in “Biochemical Pharmacology” ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.
Baricitinib may not always prevent relapse in alopecia areata.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
148 citations
,
May 2012 in “The American Journal of Human Genetics” Cantú syndrome is caused by mutations in the ABCC9 gene.
August 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.
1 citations
,
January 1978 in “PubMed” Certain chemical changes to cortisol and progesterone can increase or decrease their ability to inhibit hair growth.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
July 2012 in “European journal of cancer” MPA increases cancer spread by boosting Eph A2 activity.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
11 citations
,
January 1998 in “Dermatology” Spironolactone works well for acne and hirsutism, isotretinoin is very effective for acne and may have antiandrogenic effects, and 5 alpha-reductase inhibitors should be considered antiandrogens.
Higher iodine levels in children's hair may help cure tinea capitis during puberty.
2 citations
,
November 2024 in “JCEM Case Reports” Inhaled substances in e-cigarettes can cause hormone imbalances similar to congenital adrenal hyperplasia.
21 citations
,
April 2018 in “Journal of Dermatological Science” Cilostazol helps hair grow by making hair root cells grow faster and changing growth factor levels.
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.